Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence actually shows, and where families should turn instead
The myth worth correcting first: a lower BMI or younger age doesn't open a side door
One of the most common misconceptions our prescribers encounter is the idea that Wegovy's age restriction is a technicality that can be worked around, by framing it as an off-label request, sourcing it abroad, or finding a provider willing to interpret the rules generously. None of those routes are appropriate. The MHRA's authorisation is unambiguous: semaglutide for weight management (Wegovy) is licensed for adults. A GPhC-registered prescriber who issued a Wegovy prescription to a person under 18 for weight loss would be acting outside the product licence. That is a clinical and regulatory line, not a commercial preference.
It is also worth being clear about what "off-label" means here. Off-label prescribing does exist in medicine, but it requires specific clinical justification, specialist oversight, and governance, it is not a route through an online pharmacy. For teenagers with significant weight-related health conditions, the right setting is a paediatric specialist or a commissioned NHS tier 3/4 service, not a private online consultation.
The NHS NHS medicines page on semaglutide is the easiest place to confirm this in under a minute: the patient information clearly states the medicine is for adults.
What the adolescent trial data actually shows, and what it doesn't
A phase 3 trial (STEP TEENS) did investigate semaglutide 2.4mg in adolescents aged 12–17 with obesity, and the results were published in the New England Journal of Medicine. Participants who completed the 68-week trial showed meaningful reductions in BMI. The data are real, and they matter scientifically. But a trial result and a UK marketing authorisation are separate things. The MHRA reviews safety, efficacy and quality data through its own process before granting a licence; STEP TEENS data has not translated into a UK licence for under-18s at the point this page was written.
What remains genuinely uncertain is whether, and when, a UK adolescent licence for semaglutide or another GLP-1 medicine might follow. Regulatory timelines are unpredictable. Families should not make decisions based on the possibility of future approvals. If you want a thorough look at what the evidence currently says about Wegovy for teens, including what the trial data covers and where the licensing boundaries sit, our dedicated page works through it in detail.
For a broader picture of what Wegovy is, how it works in adults, and what the adult trial programme showed, the Wegovy overview on this site covers the detail. Context helps when navigating these conversations with a clinician.
Where teenagers with weight concerns should actually go
In the UK, the appropriate clinical pathway for a young person with significant weight-related health concerns runs through their GP first. A GP can assess whether a referral to a specialist paediatric or adolescent weight management service is warranted. NHS England and NICE recognise that weight in children and adolescents requires a different approach from adult care, one that includes behavioural, nutritional and psychological support alongside any medical consideration. These are not simply junior versions of adult services.
Privately, some specialist centres offer adolescent weight management, but they are staffed by paediatricians and multi-disciplinary teams, not general prescribers. The British Obesity and Metabolic Surgery Society and specialist NHS tier 4 services have experience with complex adolescent cases. None of these involve obtaining a GLP-1 pen through an online pharmacy.
The NHS England guidance on weight management injections is written for adult services, but it illustrates how even the adult pathway involves structured support, the adolescent pathway requires at least the same level of care, and usually more.
If you are an adult researching your own options, the weight-loss treatment overview explains the medicines currently available for adults in the UK and how a private clinical assessment works.
Situations closely related to this one: pregnancy, diabetes and other conditions
Parents and carers sometimes ask about Wegovy in contexts that overlap with this one, a teenager who has been diagnosed with type 2 diabetes, for example, or a young person approaching adulthood. These are distinct clinical questions, each with their own evidence base and licences. Semaglutide is licensed for type 2 diabetes in adults under the brand name Ozempic; the weight-management licence (Wegovy) is separate, and neither covers under-18s without specialist oversight. Our page on Wegovy and type 2 diabetes covers the adult picture.
Adults who do meet the licensed criteria and want to understand what a private consultation involves can read more on our page about online access to Wegovy for younger adults. For those with questions about Wegovy during pregnancy or when planning a family, the guidance is similarly clear: anyone who wants to understand whether you can take Wegovy if pregnant will find that our dedicated page covers the recommendations carefully, including advice on stopping treatment well in advance of trying to conceive. The Wegovy and pregnancy page covers this carefully.
Our clinical team is available seven days a week for adult patients with questions that arise during treatment. If you are looking for support for a young person, the most important first call is to their GP. That is where an appropriate referral begins.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.